Taysha Gene Therapies, Inc. [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	10-Q	10-Q	10-Q	10-K	10-Q	10-Q
Revenues	2.4	4.7	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	2.4	4.7	0.0	0.0	0.0	0.0	0.0	0.0
Gross margin	100.0%	100.0%
Selling, general and administrative [+]	25.8	21.3	8.7	33.4	49.7	11.8	11.2	10.1
General and administrative			8.7			11.8	11.2	10.1
Research and development			16.4			37.9	39.5	30.6
Other operating expenses	2.4	0.9		1.4	-0.8
EBITDA [+]			-24.8			-49.5	-50.5	-40.7
EBITDA growth	-25.9%	-64.2%	-50.9%	-14.4%	52.5%	169.7%	235.9%
EBITDA margin	-1077.7%	-371.7%
Depreciation and amortization			0.3			0.2	0.2	0.1
EBIT [+]	-25.8	-17.5	-25.1	-34.8	-48.9	-49.7	-50.7	-40.8
EBIT growth	-25.9%	-64.2%	-50.5%	-14.6%	52.3%	170.7%	237.0%
EBIT margin	-1077.7%	-371.7%
Non-recurring items					1.3
Interest expense			1.2			0.7	0.5	0.2
Interest expense	1.4	1.4	1.2	0.7	0.7	0.7	0.5	0.2
Other income (expense), net [+]	2.7	1.2	0.0	1.5	0.5	0.0	0.0	0.0
Other non-ooperating expenses			0.0
Other		-0.1	0.0		-0.2
Pre-tax income	-24.6	-17.6	-26.3	-34.1	-50.3	-50.4	-51.2	-40.9
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-24.6	-17.6	-26.3	-34.1	-50.3	-50.4	-51.2	-40.9
Net margin	-1027.1%	-374.5%

Basic EPS [+]	($0.38)	($0.28)	($0.64)	($0.85)	($1.32)	($1.34)	($1.35)	($1.09)
Growth	-54.9%	-78.9%	-52.3%	-22.2%	52.3%	29.1%	5.1%
Diluted EPS [+]	($0.38)	($0.28)	($0.64)	($0.85)	($1.32)	($1.34)	($1.35)	($1.09)
Growth	-54.9%	-78.9%	-52.3%	-22.2%	52.3%	29.1%	5.1%

Shares outstanding (basic) [+]	64.2	63.3	40.9	40.1	38.2	37.7	38.0	37.5
Growth	60.0%	65.7%	7.7%	7.1%	3.2%	113.1%	223.9%
Shares outstanding (diluted) [+]	64.2	63.3	40.9	40.1	38.2	37.7	38.0	37.5
Growth	60.0%	65.7%	7.7%	7.1%	3.2%	113.1%	223.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.